ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.91), $0.02 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $3.84 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Goldman Sachs Upgrades Primoris Services Corporation (PRIM) to Neutral
• JPMorgan Starts Accton Technology Corp. (2345:TT) at Overweight